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ABSTRACT
Objective: To compare the performance
characteristics of cell-bound complement (C4d)
activation products (CBCAPS) on erythrocyte (EC4d)
and B cells (BC4d) with antibodies to double-stranded
DNA (anti-dsDNA) and complement C3 and C4 in
systemic lupus erythematosus (SLE).
Methods: The study enrolled 794 subjects consisting of
304 SLE and a control group consisting of 285 patients
with other rheumatic diseases and 205 normal individuals.
Anti-dsDNA and other autoantibodies were measured
using solid-phase immunoassays while EC4d and BC4d
were determined using flow cytometry. Complement
proteins were determined using immunoturbidimetry.
Disease activity in SLE was determined using a nonserological Systemic Lupus Erythematosus Disease
Activity Index SELENA Modification. A two-tiered
methodology combining CBCAPS with autoantibodies to
cellular and citrullinated antigens was also developed.
Statistical analyses used area under receiver operating
characteristic curves and calculations of area under the
curve (AUC), sensitivity and specificity.
Results: AUC for EC4d (0.82±0.02) and BC4d (0.84
±0.02) was higher than those yielded by C3 (0.73±0.02)
and C4 (0.72±0.02) (p<0.01). AUC for CBCAPS was also
higher than the AUC yielded by anti-dsDNA (0.79±0.02),
but significance was only achieved for BC4d (p<0.01).
The combination of EC4d and BC4d in multivariate testing
methodology with anti-dsDNA and autoantibodies to
cellular and citrullinated antigens yielded 80% sensitivity
for SLE and specificity ranging from 70% (Sjogren’s
syndrome) to 92% (rheumatoid arthritis) (98% vs.
normal). A higher proportion of patients with SLE with
higher levels of disease activity tested positive for elevated
CBCAPS, reduced complement and anti-dsDNA (p<0.03).
Conclusions: CBCAPS have higher sensitivity than
standard complement and anti-dsDNA measurements, and
may help with the differential diagnosis of SLE in
combination with other autoantibodies.

KEY MESSAGES
▸ CBCAPS have higher sensitivity for SLE than
standard complement measures.
▸ CBCAPS in multivariate assay panel yield high
sensitivity and specificity for SLE.

INTRODUCTION
The diagnosis of systemic lupus erythematosus (SLE) remains challenging partly
because of the heterogeneity of the disease,
its evolutive nature and also because there
are signiﬁcant limitations with currently available diagnostic immunology tests.1 2 In addition, SLE can be associated with irreversible
and unpredictable organ damage, and the
disease results in substantial economic
burden to the patient and healthcare
system.3 4 Therefore, an accurate diagnosis is
critical. Currently, the diagnosis of SLE rests
on a combination of clinical features (history
and physical examination), other tests and
immunological testing along with classiﬁcation criteria.5 6
Among the immunological laboratory measurements performed routinely, the detection of antinuclear antibodies (ANA) is
pivotal for screening purposes, owing to its
high sensitivity. However, the ANA test is
imperfect with a 10%–25% false positive rate
among healthy individuals.7 8 More speciﬁc
immunological tests such as antibodies to
double-stranded DNA (anti-dsDNA) and/or
anti-Smith (anti-Sm) are also useful in diagnosing SLE, but these markers lack sensitivity.9 Other autoantibodies to cellular antigens
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including antibodies to extractable nuclear antigens
(ENA: Sjogren’s syndrome (SS)-A/Ro, SS-B/La,
Centromere (CENP), Jo-1 U1RNP, scleroderma (Scl)-70)
are also routinely measured in the clinical immunology
laboratory, and while of value, none of these markers
have sufﬁcient predictive value on their own to differentiate SLE from other connective tissue diseases.9 Since
patients with SLE often share many clinical features with
other connective tissue diseases, the potential for misdiagnosis is not insigniﬁcant. It follows that the availability of more sensitive and speciﬁc diagnostic tests is
highly desirable.
Many patients with SLE experience activation of the
classical complement pathway, resulting in reduced complement levels and formation of complement C4 activation products (CBCAPS) that are stably deposited on
various cell membranes including erythrocytes (EC4d)
and B-lymphocytes (BC4d).10–12 In particular, the deposition of C4d on erythrocytes has a signiﬁcant impact on
erythrocyte membrane deformability,13 thereby potentially impairing the ability of red blood cells to deliver
oxygen to tissues. These CBCAPS were initially reported
as valuable in SLE diagnostics,11 and their performance
characteristics were recently validated in a prospective
multicentre study.10 In the present study, we sought to
compare the sensitivity of CBCAPS with reduced complement C3/C4 levels as these markers are often used to
support SLE diagnosis and are now part of the new
Systemic Lupus International Collaborating Clinics
(SLICC) criteria for classifying SLE.14 We also compared
the performances of CBCAPS with anti-dsDNA antibody
levels and developed a multivariate diagnostic methodology combining these markers with other autoantibodies to cellular and citrullinated antigens. Finally, in
this large cross-sectional study, the relationship between
CBCAPS, standard complement measurements and
anti-dsDNA antibody levels and disease activity was
evaluated.

METHODS
This study was multicentred and enrolled adult patients
with SLE who fulﬁlled the 1982 American College of
Rheumatology (ACR) classiﬁcation criteria for SLE,5 6
patients with other rheumatic diseases and normal healthy
volunteers. Methods have been described in detail elsewhere.10 Two cohorts were deﬁned. The ﬁrst cohort
(cohort 1) consisted of 593 subjects previously characterised and enrolled from April to August 2010 (210 SLE,
120 rheumatoid arthritis (RA), 21 Scl, 9 SS, 16 polymyositis/dermatomyositis (PM/DM), 12 other rheumatic diseases and 205 normal healthy volunteers).10 The second
cohort (cohort 2) consisted of 201 subjects (94 SLE, 41
RA, 14 Scl, 24 SS, 11 PM/DM and 17 other diseases)
enrolled from June 2011 to September 2013. The study
was approved by internal review boards at each participating site, and all subjects provided informed consent. All
autoantibodies, complement C3/C4 and CBCAPS
2

determinations were performed in our centralised clinical
laboratory. ANA, anti-dsDNA and anti-mutated citrullinated vimentin (anti-MCV) were determined using validated ELISA, while CBCAPS (EC4d and BC4d expressed
as net mean ﬂuorescence intensity (MFI)) were determined using ﬂow cytometry.10 All analytes measured were
stable during transportation at least 48 h post-phlebotomy.
All anti-dsDNA-positive results (as per manufacturer
cut-off) detected by ELISA were conﬁrmed using the
Crithidia Luciliae immunoﬂuorescence assay (Inova
Diagnostics, San Diego, California, USA).15 Antibodies to
ENA (SS-A/Ro, SS-B/La, CENP, Scl-70, Jo-1, anti-Sm,
U1RNP) were measured using ﬂuorescent-enzyme immunoassays (ThermoFisher, Uppsala, Sweden). Cut-offs
recommended by the manufacturer were used for all autoantibodies. Complement C3 and C4 levels were determined using immunoturbidimetry (The Binding Site, San
Diego, California, USA), and low complement cut-offs for
C3 or C4 were set at a concentration lower than the 95th
centile of normal healthy subjects. Among patients with
SLE, disease activity was determined using the Systemic
Lupus Erythematosus Disease Activity Index SELENA
Modiﬁcation (SELENA-SLEDAI)16 subscore (without the
immunology components (i.e. low complement and
anti-dsDNA reactivity—modiﬁed SELENA-SLEDAI)).
Statistical analysis was conducted using the R software
V.2.15. Statistical analyses used area under receiver operating characteristic (ROC) curves and calculations of
area under the curve (AUC), sensitivity and speciﬁcity
(SLE vs. rheumatic disease controls and normal healthy
volunteers). A two consecutive tier methodology was
used to develop the multivariate assay panel10 in which
AUC calculation included both tiers, with tier 1-positive
samples given an index value consistent with a logistic
function of 0.99. The reported performance statistics
(sensitivity,
speciﬁcity)
were
calculated
using
leave-one-out cross-validation. Correlation between variables was evaluated using non-parametric Spearman’s
rank tests while differences between groups were evaluated using Kruskal–Wallis test. Differences in sensitivity
and speciﬁcity between the two cohorts of subjects were
evaluated using χ2 test.
RESULTS
Patient characteristics
Characteristics for the 794 subjects enrolled are presented in table 1 and consisted of 304 SLE, 161 RA, 33
SS, 35 Scl, 27 PM/DM, 29 patients with other rheumatic
diseases and 205 normal healthy volunteers. As
expected, the ANA test (≥20 units) was a sensitive
(89%) yet non-speciﬁc marker in distinguishing SLE
from other rheumatic diseases (53%). Conversely,
anti-dsDNA and anti-Sm were less sensitive (33% and
14%, respectively) but highly speciﬁc for SLE (>95%; at
manufacturer cut-offs). Increased titres for anti-MCV
(>70 units), SS-B/La (>10 units), Scl-70 (>10 units),
CENP (>10 units) and Jo-1 (>10 units) were speciﬁc in
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Table 1 Characteristics of 794 subjects and single marker assay results
Age (years)
Gender (% female)
Ethnicity Caucasians (%)
African–Americans (%)
Asians (%)
Hispanics (%)
Other (%)
Duration of disease (years)
ANA ≥20 units (%)
dsDNA >301 units (%)
Anti-Sm >10 units (%)
Anti-MCV >70 units (%)
Jo1 >10 units (%)
Scl-70 >10 units (%)
SS-A/Ro >10 units (%)
SS-B/La >10 units (%)
CENP >10 units (%)
Reduced C3 (%)
Reduced C4 (%)
Reduced C3 or C4 (%)
U1 RNP >10 units (%)
EC4d net MFI
>14 units (%)
>75 units (%)
BC4d net MFI
>60 units (%)
>200 units (%)
Antibody specificity comp. (%)

SLE

RA

SS

Scl

PM/DM

Others

NHV

41±1
91
41
30
8
20
2
11±1
89
33
14
3
0
0
39
9
2
33
32
45
27
21±3
46
2
106±6
53
14
12

59±1
85
61
15
4
19
2
12±1
32
4
0
47
0
0
10
1
3
4
7
10
0
7±1
5
0
32±2
9
0
48

54±2
91
73
18
0
9
0
10±3
89
0
0
9
0
3
79
39
3
6
3
9
3
10±2
12
0
26±4
9
0
52

51±2
80
74
14
0
9
3
8±1
66
6
0
6
0
20
11
3
17
12
0
12
6
7±1

56±2
81
63
26
0
11
0
3±1
74
0
0
4
15
0
26
0
0
0
4
4
0
8±1
11
0
27±4
4
0
15

53±3
83
48
10
10
31
0
6±1
31
7
0
3
0
0
3
0
0
0
4
4
10
8±1
10
0
46±19
10
3
3

41±1
65
56
35
2
6
1
NA
10
0
0
0
0
0
1
0
1
6
4
8
0
5±1
1
0
23±1
1
0
1

0
32±5
6
0
46

Age, EC4d, BC4d and disease duration are expressed as average±SEM. The group of subjects with other rheumatic diseases included
granulomatosis with polyangiitis (5 patients), fibromyalgia (13 patients), vasculitis (10 patients) and antiphospholipid syndrome (1 patient)).
The antibody specificity component corresponds to positivity to either anti-MCV (>70 units), SS-B/La (>10 units), Jo-1 (>10 units), Scl-70
(>10 units) or CENP (>10 units), and was used to calculate the index score (tier 2).
ANA, antinuclear antibodies; anti-Sm, anti-Smith; dsDNA, double-stranded DNA; MFI, mean fluorescence intensity; NA, not applicable; NHV,
normal healthy volunteers; PM/DM, polymyositis/dermatomyositis; RA, rheumatoid arthritis; Scl, scleroderma; SLE, systemic lupus
erythematosus; SS, Sjogren’s syndrome; anti-MCV, anti-mutated citrullinated vimentin; EC4d, complement C4d levels on erythrocytes; BC4d,
complement C4d levels on cells; CENP, Centromere extractable nuclear antigen.

distinguishing SLE from RA, SS, Scl and PM/DM subjects, respectively (table 1). Among subjects with rheumatic diseases other than SLE, 40% tested positive for one
or more of these 5 speciﬁc antibodies (anti-MCV, SS-B/
La, CENP, Scl-70 and Jo-1). EC4d and BC4d levels were
several fold higher in SLE than other rheumatic
diseases.
CBCAPS have higher sensitivity than low complement C3/C4
and anti-dsDNA
The performance characteristics of EC4d and BC4d
were compared with those of reduced complement
(C3/C4) and anti-dsDNA in a total of 764 subjects (288
SLE and 476 non-SLE (274 other rheumatic diseases
and 202 healthy subjects); serum was not available 30
subjects). Lower complement C4 levels were associated
with higher EC4d levels (R=−0.249; p<0.001) and BC4d
levels (R=−0.343; p<0.001). Similarly, lower complement
C3 levels correlated with higher CBCAPS (EC4d:
−0.248; BC4d: −0.314; p<0.001). Area under the ROC
curves for EC4d (0.82±0.02 (SEM)) and BC4d (0.84

±0.02) was higher than those yielded by C3 (0.73±0.02)
and C4 (0.72±0.02) ( p<0.001) (ﬁgure 1). Area under
the ROC curves for CBCAPS was also higher than the
AUC yielded by anti-dsDNA (0.79±0.02), but signiﬁcance
was achieved for BC4d ( p=0.009) and not EC4d
( p=0.108). The combination of reduced complement
proteins (C3 or reduced C4, each below their respective
cut-offs yielding 95% speciﬁcity) was 91% speciﬁc
against the control group, and sensitivity was 44%. At
that speciﬁcity, anti-dsDNA was 42% sensitive while elevated CBCAPS (EC4d or BC4d each above their respective cut-offs yielding 95% speciﬁcity) was 66% sensitive.
Performance characteristics of multivariate assay panel using
CBCAPS
The multivariate diagnostic methodology involved two
consecutive tiers of analysis (ﬁgure 2). Tier 1 relied on
positivity for anti-dsDNA, anti-Sm or elevated EC4d (>75
net MFI) and BC4d (>200 net MFI). A total of 140
patients with SLE (46%), 9 patients with other diseases
(3%) and 1 normal healthy subject (<1%) were positive
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Figure 1 Receiver operating curve of soluble C3, C4,
antibodies to double-stranded DNA (anti-dsDNA) compared
with complement C4d levels on erythrocytes (EC4d) and on B
cells (BC4d) in systemic lupus erythematosus (SLE) (n=288)
vs. non-SLE (n=476). Area under the receiver operating
characteristic curves for EC4d was 0.82±0.02 (SEM)), 0.84
±0.02 for BC4d, 0.73±0.02 for C3, 0.72±0.02 for C4d and
0.79±0.02 for anti-dsDNA.

for any one of the tier 1 markers. Altogether, the speciﬁcity (vs. other rheumatic diseases) for tier 1 markers was
96% for anti-dsDNA and >99% for EC4d (>75 net NFI),
BC4d (>200 net MFI) and anti-Sm. Tier 2 and the index
score were determined among subjects negative in tier 1
(644 subjects including 164 SLE, 276 other diseases and
204 normal healthy subjects). This index score (output
of logistic regression) was calculated by combining an
ANA component (using ANA cut-offs at 20 and 60
units), a CBCAPS component (sum of log normalised
EC4d and BC4d net MFI) and an antibody speciﬁcity
component (corresponding to positivity to either
anti-MCV, SS-B/La, CENP, Scl-70 or Jo-1). As presented
in ﬁgure 3, 102 of the 164 patients with SLE analysed in
tier 2 (62%) presented with an index score >0 while 62
presented a score <0. Conversely, among the 276 subjects with rheumatic diseases other than SLE, a total of
245 subjects (148 RA, 23 SS, 32 Scl, 20 PM/DM and 22
others) presented with an index score <0, thus yielding
a speciﬁcity of 89% (245/276). Altogether, when the two
tiers were combined, the overall sensitivity for SLE was
80% (242/304) while the overall speciﬁcity in distinguishing SLE from other diseases ranged from 70%
(23/33 SS) to 92% (148/161 RA) (overall speciﬁcity was
86% (245/285)). Speciﬁcity in distinguishing SLE from
normal subjects was 98% (201/205).
The difference in sensitivity between the two cohorts
(cohort 1=81% (170/210) vs. cohort 2=77% (72/94))
was not statistically signiﬁcant ( p=0.473). Also, the
4

Figure 2 Multivariate assay panel for systemic lupus
erythematosus (SLE) diagnosis. Two-tier diagnostic
methodology for SLE diagnosis. Positivity in tier 1 consisted
of reactivity to antibodies to double-stranded DNA
(anti-dsDNA) (confirmed using Crithidia), anti-Smith (anti-Sm)
or elevated complement C4d levels on erythrocytes (EC4d)
and on B cells (BC4d). The index score (tier 2) was calculated
among tier 1-negative subjects. Estimates with intercept from
multivariate logistic regression are provided. The antinuclear
antibodies component (ANA comp) used two thresholds and
was affected with a value of 0 (ANA <20 units), a value of 1
(20≤ ANA <60 units) or a value of 2 (ANA ≥60 units). The
complement C4 activation products (CBCAPS) component
corresponds to log normalised EC4d plus BC4d values each
affected by their coefficient. The antibody specificity
component (Spec. Comp) was affected with a value of 0 (antimutated citrullinated vimentin (anti-MCV), Sjogren’s syndrome
(SS)-B, Centromere extractable nuclear antigen (CENP), Jo-1,
scleroderma (Scl)-70 all negative) or 1 (either anti-MCV,
SS-B, CENP, Jo-1, Scl-70 positive). For example, a tier
1-negative subject presenting with ANA=35 units, EC4d =15
net mean fluorescence intensity (MFI), BC4d=35 net MFI and
Scl-70=50 units would present an index score of=−5.30
+0.98×1+0.31×log (15)+1.03×log(35)−2.48°1=−2.3.

difference in speciﬁcity in distinguishing SLE from
other diseases was not statistically signiﬁcant between
the two cohorts (cohort 1= 87% (155/178) vs. cohort
2=84% (90/107); p=0.602).
Finally, the performance characteristics of this two-tiered
multivariate model combining CBCAPS with antibodies to
cellular and citrullinated antigens (as presented in ﬁgure 2)
were compared with those achieved without CBCAPS or
without the antibody speciﬁcity component. As presented
in table 2, the two-tiered model combining ANA,
anti-dsDNA and anti-Sm (model #1) resulted in modest performances (AUC=0.781) with overall sensitivity of 89% and
speciﬁcity of 53% (speciﬁcity in distinguishing normal subjects was 90%). However, the addition of CBCAPS (in both
tier 1 and tier 2; model #3) signiﬁcantly augmented the performances of the former model (AUC=0.894; p<0.001).
Further enhancement in the speciﬁcity in distinguishing
SLE from other connective tissue diseases (SS +18%; systemic sclerosis +34%; PM/DM +15% and RA +15%) was
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Figure 3 Performance
characteristics for multivariate
assay SLE panel. The number of
subjects in tier 1 and tier 2
(positive and negative) is
indicated. Median index score
(IQR) in tier 2 is provided. Overall
diagnostic sensitivities (sens.) are
provided for SLE. Specificities for
other rheumatology diseases
(spec.) are also given. NHV,
normal healthy volunteers; SLE,
systemic lupus erythematosus;
PM/DM, polymyositis/
dermatomyositis; RA, rheumatoid
arthritis.

obtained with the addition of the antibody speciﬁcity component (AUC=0.913; p<0.01; model #4).
Contribution of disease activity to test sensitivity
The modiﬁed SELENA-SLEDAI subscores (nonserological SELENA-SLEDIA) together with anti-dsDNA,

low complement C3/C4 and CBCAPS were available in
273 of the 304 SLE subjects (median 1.0; range 0–23).
Among patients with a modiﬁed SELENA-SLEDAI subscore of 0 (131/273 patients), the sensitivity was 29% for
anti-dsDNA, 36% for low complement, 62% for elevated
CBCAPS and 77% for the two-tiered methodology

Table 2 Stepwise addition of CBCAPS and antibody components to ANA, anti-dsDNA and anti-Sm serologies
Model #1
Tier1
Tier 2
Total sensitivity
(%)
Total specificity
(others) (%)
Sjogren’s
syndrome (%)
Scleroderma (%)
PM/DM (%)
RA (%)
Other diseases (%)
Specificity (NHV)
(%)
Two-tiered AUC

dsDNA;
Sm
ANA*

Model #2: model #1
+specificity component

Model #3: model
#1+CBCAPS

Model #4: model #1+CBCAPS
+specificity component

dsDNA; Sm

dsDNA; Sm; EC4d;
BC4d
ANA*+CBCAPS‡

dsDNA; Sm; EC4d; BC4d
ANA*+CBCAPS‡+Antibody specificity†

84

80

89

ANA*+Antibody
specificity†
83

53

76

70

86

12

61

52

70

34
26
67
69
90

77
41
86
69
91

57
59
77
76
95

91
74
92
76
98

0.781

0.804

0.894

0.913§

The diagnostic methodology involved two consecutive ‘tiers’ of analysis in which the aggregated diagnostic value of anti-dsDNA, anti-Sm,
ANA combined with CBCAPS (EC4d and BC4d) and antibody specificity component (positivity to either anti-MCV, SS-B/La, Jo-1, Scl-70 or
CENP) (model #4 as presented figure 1) was compared with model #1.
Model#1 relied on anti-dsDNA (>301 units confirmed by Crithidia) or anti-Sm (>10 units) reactivities in tier 1. Tier 2 was determined among
subjects negative in tier 1 and consisted of an index score of the ANA component only (as defined in figure 1 legend); positivity for the index
score (>0) was indicative of SLE, and the two-tier combination resulted in the overall performance characteristics (total sensitivity and total
specificity). The stepwise addition of CBCAPS (model #3) and the antibody specificity component (model #4) to model #1 maximised the
performances characteristics.
Total sensitivity and specificity are SLE vs. all others diseases. The individual sensitivities and specificities are SLE vs. the individual disease.
*ANA component.
†Antibody specificity component.
‡CBCAPS component.
§p<0.01 vs. model 1, 2 and 3.
ANA, antinuclear antibodies; anti-Sm, anti-Smith; AUC, area under the curve; CBCAPS, complement C4 activation products; anti-dsDNA,
antibodies to double-stranded DNA; PM/DM, polymyositis/dermatomyositis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus;
NHV, normal healthy volunteers; anti-MCV, anti-mutated citrullinated vimentin; EC4d, complement C4d levels on erythrocytes; BC4d,
complement C4d levels on cells; CENP, Centromere extractable nuclear antigen; Scl, scleroderma; SS, Sjogren’s syndrome.
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Figure 4 Positivity rate for antibodies to double-stranded DNA (anti-dsDNA), low complement, high complement C4 activation
products (CBCAPS) and two-tiered methodology stratified by disease activity score. Disease activity was determined by using the
non-serological Systemic Lupus Erythematosus Disease Activity Index SELENA Modification (SELENA-SLEDAI) score (without
anti-dsDNA and low complement). Anti-dsDNA positivity cut-off was at 301 units, low complement corresponds to reduced C3 or
C4, high CBCAPS corresponds to EC4d>14 net mean fluorescence intensity (MFI) or BC4d>60 net MFI. The number in each of
the non-serological SELENA-SLEDAI category is given.

(ﬁgure 4). Among SLE, those positive in tier 1 presented higher disease activity as assessed using the
SELENA-SLEDAI subscore (3.3±0.4 points, average
±SEM) than those positive (1.9±0.3 points) or negative
in tier 2 (1.4±0.3) (Kruskal–Wallis test: p=0.002). Higher
level of disease activity across three SELENA-SLEDAI
subscore groups (0, 1–6 and >6) was associated with a
higher proportion of patients testing positive for elevated CBCAPS ( p=0.027) (χ2 test for homogeneity on a
3×2 contingency table). Similarly, higher level of disease
activity was also associated with a higher proportion of
patients testing positive for reduced complement
( p=0.002) and positive anti-dsDNA ( p=0.005). Among
patients with SLE with less active disease (modiﬁed
SELENA-SLEDAI subscore=0), the difference in sensitivity was 26% greater for elevated CBCAPS (62%) than
for reduced complement C3 or C4 (36%) ( p<0.001).
Furthermore, the difference in sensitivity remained
higher (17%) for CBCAPS compared with low complement among patients with SLE having a modiﬁed
SELENA-SLEDAI subscore >6 points but without reaching statistical signiﬁcance ( p=0.21).

DISCUSSION
Because limitations to currently available immunological
tests can result in underdiagnosis of SLE and inappropriate treatment,17 validation of new diagnostic biomarkers
is needed. Although the SLE classiﬁcation criteria established by the ACR and more recently SLICC are being
used to diagnose SLE, these instruments were initially
developed for clinical research and not as diagnostic criteria. Also, because of the evolution of organ involvement
and laboratory abnormalities in SLE, it may take years for
6

any given patient to meet the criteria.18 It follows that
improvement in currently available laboratory tests and
diagnostic immunology methods to assist clinicians with
the diagnosis of the disease is warranted. This study
builds upon our initial report that CBCAPs assays add signiﬁcant value to accurate SLE diagnosis when combined
with routinely determined ANA and anti-dsDNA,10 and
we now report here that elevated EC4d or BC4d have a
22% higher sensitivity than reduced C3/C4, one of the
components of the new SLICC criteria.14 It follows that
the determination of CBCAPS could help address some
of the limitations of reduced complement C3/C4 levels
in the diagnosis of SLE. For example, complement activation and C3/C4 consumption in SLE may be masked by
the production of these complement proteins as a function of inﬂammation while the detection of CBCAPS is de
facto associated with previous complement activation.19
The results of this research suggest that the determination of CBCAPS may be another valuable diagnostic
biomarker for SLE. However, while greater sensitivity was
achieved with CBCAPS than for reduced complement
proteins, the overall sensitivity was modest (i.e. 66%),
thereby indicating that the addition of other markers
would be warranted to achieve improved diagnostic performances in clinical practice. Here, we have integrated
antibodies to ENA into our diagnostic methodology and
included a second cohort of 201 subjects. Our original
two-tiered diagnostic methodology relied on positivity
for anti-dsDNA (tier 1) and a weighed score (tier 2)
combining ANA titres, EC4d and BC4d with anti-MCV
to maximise speciﬁcity in distinguishing patients with
SLE from patients with RA. In this methodology, tier 1
relied on highly speciﬁc markers for SLE and included
positivity for anti-dsDNA and anti-Sm (both part of the
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ACR classiﬁcation criteria for SLE),5 6 14 with elevated
EC4d and BC4d. As expected, the combination of tier 1
markers yielded high speciﬁcity (>96%). Tier 2 determination among tier 1-negative subjects consisted of a
weighed score comprising an ANA component, a
CBCAPS component (EC4d and BC4d densities) minus
a speciﬁcity component composite of positivity for
anti-MCV, SS-B/La, CENP, Scl-70 or Jo-1. The inclusion
of SS-B/La maximised the speciﬁcity of the method in
distinguishing SLE from patients with SS. Similarly, the
inclusion of CENP and Scl-70 maximised the speciﬁcity
in distinguishing SLE from those with Scl, while the
inclusion of Jo-1 maximised the speciﬁcity for PM/DM
subjects (table 2). Moreover, the speciﬁcity of the diagnostic methodology in distinguishing SLE from RA was
maintained with the addition of anti-MCV. Altogether,
the two-tier model achieved a balanced 80% sensitivity
for SLE (34% improvement over tier 1 only) with a speciﬁcity of 86%. All serological tests that were part of our
diagnostic immunology method used widely distributed
platforms (e.g. ELISA or ﬂuorescent-enzyme immunoassays) and it is important to keep in mind that the overall
performance characteristics of our multivariate method
could potentially differ if other platforms such as laser
bead immunoassay, chemiluminescence immunoassay or
line immunoassays20 were employed. However, there is
usually a reasonable concordance between the various
methods
and
reagents
offered
by
various
manufacturers.21
We also evaluated whether the combinations of these
complementary markers in a multivariate assay panel
collectively outperformed the performance characteristics of single markers. Our results indicated that the
aggregate value of CBCAPS with serological markers outperformed the best performances achieved by combining the single serological markers together. These data
not only illustrate the value of CBCAPS as complementary markers to commonly determined serologies but
also the power of combining multianalytes in multivariate assay panels. The major strength of our study was the
large number of patients enrolled and the fact that all
laboratory analyses were centralised in only one clinical
laboratory. However, we acknowledge that additional
studies should establish the performance characteristics
of our diagnostic methodology in distinguishing SLE
from diseases such as antiphospholipid syndrome,
primary ﬁbromyalgia syndrome, autoimmune hepatitis,
undifferentiated connective tissue diseases and autoimmune thyroiditis. It is also not known whether abnormal CBCAPS selectively indicates activity in a particular
organ system (e.g. kidney) and additional studies will be
essential to address this point.
The sensitivity of low complement, elevated CBCAPS,
anti-dsDNA and our multivariate two-tiered method was
compared between patients with various levels of disease
activity
as
determined
using
the
modiﬁed
SELENA-SLEDAI subscore (without the low complement and anti-dsDNA components). Our analysis

revealed that the sensitivity for elevated CBCAPS outperformed low complement among patients with active and
inactive disease, and that higher sensitivity was observed
using the multivariate panel. Thus, elevated CBCAPS is
more likely among patients with active disease, and these
data suggest that CBCAPS could help monitor SLE
disease activity. Furthermore, the higher sensitivity of
CBCAPS compared with reduced complement and
anti-dsDNA was particularly signiﬁcant in SLE having a
modiﬁed SELENA-SLEDAI score of 0. Thus, CBCAPS
may be particularly important for diagnosing SLE in
patients having less active disease, such as outpatients with
early or mild SLE. Whether the patients having inactive
disease and complement activation will become clinically
active is not known, and prospective study will help establish whether CBCAPS can predict disease ﬂares.
In conclusion, CBCAPS have a higher diagnostic sensitivity than reduced complement and anti-dsDNA. The
assay panel combining CBCAPS with antibodies to cellular and citrullinated antigens is sensitive and speciﬁc for
SLE and may be clinically useful to help diagnose SLE.
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